Copy to clipboard 
Researchers at the Hospital for Special Surgery have been awarded an $800,000 grant from Orthopaedic Research and Education Foundation (OREF). Funds will support a clinical trial on the use of stem cell therapy to improve outcomes in rotator cuff repair.
The >50-patient, 2-year Phase II trial will evaluate safety and efficacy of stromal vascular fraction cells in improving outcomes for patients who undergo arthroscopic rotator cuff repair, specifically tracking strength and range of motion measurements, imaging assessments of muscle and tendon regeneration and patient-reported outcome scores. The primary outcome measure will be shoulder strength.
To date, this is the largest grant given in OREF history.
Source: Hospital for Special Surgery
Other stem cell research throughout 2017:
- Andrews Institute for Orthopaedics & Sports Medicine announced a randomized, multi-center Phase II U.S. FDA-observed clinical trial evaluating use of a patient’s own stem cells to regenerate knee cartilage. This is reportedly the first time that stem cells will be evaluated in a clinical trial for the ability to regenerate cartilage in massive knee cartilage injuries. The 6-year study may end early if results indicate statistical significance.
- ASC Biosciences received $1.5MM in staged funding. The development stage biotechnology company owns a proprietary platform of Multipotent Adult Stem Cells (MASCs) that can differentiate into cartilage, bone, tendon, muscle, ligaments, etc. ASC has developed Chondrofelt, a matrix intended for use in microfracture to repair articular cartilage defects.
- Orthocell entered into a research collaboration agreement with DePuy Synthes Products for its Ortho-ATI® stem cell treatment for tendon and ligament regeneration. Ortho-ATI is a non-surgical approach to treat chronic, treatment-resistant tendon injuries that have a significant negative effect on daily living activities.
- Sanford Health is attempting the use of fat-based stem cell treatments to heal small and partial thickness rotator cuff tears.
Researchers at the Hospital for Special Surgery have been awarded an $800,000 grant from Orthopaedic Research and Education Foundation (OREF). Funds will support a clinical trial on the use of stem cell therapy to improve outcomes in rotator cuff repair.
The >50-patient, 2-year Phase II trial will evaluate safety and efficacy of stromal...
Researchers at the Hospital for Special Surgery have been awarded an $800,000 grant from Orthopaedic Research and Education Foundation (OREF). Funds will support a clinical trial on the use of stem cell therapy to improve outcomes in rotator cuff repair.
The >50-patient, 2-year Phase II trial will evaluate safety and efficacy of stromal vascular fraction cells in improving outcomes for patients who undergo arthroscopic rotator cuff repair, specifically tracking strength and range of motion measurements, imaging assessments of muscle and tendon regeneration and patient-reported outcome scores. The primary outcome measure will be shoulder strength.
To date, this is the largest grant given in OREF history.
Source: Hospital for Special Surgery
Other stem cell research throughout 2017:
- Andrews Institute for Orthopaedics & Sports Medicine announced a randomized, multi-center Phase II U.S. FDA-observed clinical trial evaluating use of a patient’s own stem cells to regenerate knee cartilage. This is reportedly the first time that stem cells will be evaluated in a clinical trial for the ability to regenerate cartilage in massive knee cartilage injuries. The 6-year study may end early if results indicate statistical significance.
- ASC Biosciences received $1.5MM in staged funding. The development stage biotechnology company owns a proprietary platform of Multipotent Adult Stem Cells (MASCs) that can differentiate into cartilage, bone, tendon, muscle, ligaments, etc. ASC has developed Chondrofelt, a matrix intended for use in microfracture to repair articular cartilage defects.
- Orthocell entered into a research collaboration agreement with DePuy Synthes Products for its Ortho-ATI® stem cell treatment for tendon and ligament regeneration. Ortho-ATI is a non-surgical approach to treat chronic, treatment-resistant tendon injuries that have a significant negative effect on daily living activities.
- Sanford Health is attempting the use of fat-based stem cell treatments to heal small and partial thickness rotator cuff tears.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
